Kayla J. Temple, Ph.D.
Drug Discovery Scientist II
| Wheeling Jesuit University, 2007 B.S. Chemistry |
|
| Purdue University, 2013 Ph.D. Medicinal Chemistry and Molecular Pharmacology |
Phone: (615) 343-2725
Fax: (615) 778-1414
Email: kayla.temple@vanderbilt.edu
Location: Cool Springs Innovation Park
Mailing Address:
Vanderbilt University/WCNDD
Cool Springs Innovation Park
393 Nichol Mill Lane, Room 1000
Franklin, TN 37067
Biosketch and Research Interests
Kayla J. Temple is a Drug Discovery Scientist who joined the VCNDD Team in 2016 after completing two years of post-doctoral training under the tutelage of Dr. Craig Lindsley at Vanderbilt University. Kayla’s research interests include medicinal chemistry, organic synthesis, chemical biology, and drug discovery. Her current research efforts are focused on medicinal chemistry and drug discovery for CNS disorders particularly in relation to positive allosteric modulators for muscarinic acetylcholine receptor M4.
Kayla J. Temple earned her B.S. degree in Chemistry at Wheeling Jesuit University in 2007 and went on to earn her Ph.D in Medicinal Chemistry & Molecular Pharmacology at Purdue University in 2013. Kayla obtained her doctoral training under the tutelage of the late Prof. Richard A. Gibbs. The overall goal of her doctoral work was to investigate various prenylated proteins’ roles in the various stages of cancer. Her work focused on the synthesis of unique non-natural isoprenoid analogs of farnesyl- and geranylgeranyl diphosphates, with an emphasis on designing and synthesizing novel chemical tools to be used as proteomic probes.
Kayla moved to Vanderbilt in 2014 to pursue her post-doctoral training in the Lindsley Laboratory. Over the next two years, Kayla worked on several projects for which she has published several papers and patents. Her post-doctoral research was focused on the design and synthesis of G protein-coupled receptor (GPCRs) modulators such as protease activated receptor 4 (PAR4), the Gβγ-SNARE (N-ethylmaleimide-sensitive factor attachment protein receptor) complex, Muscarinic acetylcholine receptor M4, and Dopamine receptor D4 as well as of the tyrosine kinase Discoidin domain receptor 1 (DDR1) kinase.
Selected Publications
Duvernay, M.T.; Temple, K.J.; Maeng, J.G.; Blobaum, A.L.; Stauffer, S.R.; Hamm, H.E.; Lindsley, C.W. ‘Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation In Human Platelets’ Molecular Pharmacology (2017); 91(1): 39-47. {DOI: 10.1124/mol.116.106666; PMID: 27784794}
Temple, K.J.; Duvernay, M.T.; Young, S.E.; Wangdong, W.; Blobaum, A.L.; Stauffer, S.R.; Hamm, H.E.; Lindsley, C.W. ‘Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.’ Journal of Medicinal Chemistry (2016); 59(16): 7690-7695. {DOI: 10.1021/acs.jmedchem.6b00928; PMID: 27482618}
Temple, K.J.; Wright, E.N.; Fierke, C.A.; Gibbs, R.A. ‘Synthesis of Non-Natural Frame-Shifted Isoprenoid Diphosphate Analogues’ Organic Letters (2016); 18(23): 6038-6041. {DOI: 10.1021/acs.orglett.6b02977}